Concurrent Investment Advisors LLC Boosts Stock Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Concurrent Investment Advisors LLC increased its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 37.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 26,909 shares of the medical research company's stock after purchasing an additional 7,283 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Edwards Lifesciences were worth $1,950,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its holdings in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares during the period. Alyeska Investment Group L.P. bought a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $49,038,000. Dynamic Advisor Solutions LLC lifted its holdings in Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the period. Finally, Simplify Asset Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $5,979,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president owned 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,348 shares of company stock valued at $2,977,683. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Up 1.0%

Shares of NYSE:EW traded up $0.79 during trading hours on Thursday, hitting $77.98. 1,821,984 shares of the company's stock traded hands, compared to its average volume of 5,232,983. The firm has a market capitalization of $45.74 billion, a P/E ratio of 11.16, a price-to-earnings-growth ratio of 3.84 and a beta of 1.11. The business has a fifty day moving average price of $76.18 and a 200-day moving average price of $73.33. Edwards Lifesciences Corporation has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the business earned $0.66 EPS. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Truist Financial dropped their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Robert W. Baird boosted their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Finally, Citigroup restated a "buy" rating and set a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $80.40.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.